Healthcare Professionals​

This is an international website for NERLYNX® dedicated to Healthcare professionals ​​

IMPORTANT: the information on this website is based on the European Summary of Product Characteristics. Prescribing Information and indication may vary per country. You must refer to your country prescribing information. Please be aware we do not take responsibility for accessing such information which may not comply with the regulation or usage in your country.

I certify that: 

I am Healthcare Professional inside the EU and I have read the information above​.

Non Healthcare Professionals

This is an international website for NERLYNX® dedicated to Healthcare Professionals.

I am not a Healthcare Professional inside the EU.

https://www.pierre-fabre.com/en
Image
heading-Nerlynx-Neratinib--HER2-Breast-Cancer-2

Possible clinical scenarios

Take one more step for additional protection with NERLYNX

Image
Nerlynx-Neratinib--HER2+/HR+ early breast cancer- Adjuvant treatment history

Summary of the possible clinical scenarios taking into account therapeutic advances and acknowledging the different levels of evidence for NERLYNX use.37

CT, chemotherapy; eBC, early breast cancer; HER2+, human epidermal growth factor receptor 2 positive; HR, hormone receptor; pCR, pathological complete response; T-DM1, trastuzumab emtansine.
*Following trastuzumab-based treatment in HER2+ eBC, upon integration with existing treatment guidelines and careful benefit/risk evaluation on an individual patient basis.37

Contenu de la pop in (ici, un H3)

A noter que le contenu de la pop in est prise en compte pour le SEO.

Il est donc nécessaire de bien baliser les titres. Nous conseillons d'utiliser un H2 ou un H3 (pas de H1).